B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants

Acta Paediatrica, International Journal of Paediatrics

Volumn 102, Issue 8, 2013, Pages

  Mine, Kenji ^a   Ohashi, Atsushi ^a   Tsuji, Shoji ^a   Nakashima, Jun Ichi ^a   Hirabayashi, Masato ^a   Kaneko, Kazunari ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

B type natriuretic peptide; Haemodynamically significant patent ductus arteriosus; Indomethacin; Premature infants; Surgical ligation

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; INDOMETACIN;

APGAR SCORE; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HEMODYNAMICS; HUMAN; MALE; NEWBORN; PATENT DUCTUS ARTERIOSUS; PERINATAL PERIOD; PREMATURITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DUCTUS ARTERIOSUS, PATENT; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL; LIGATION; MALE; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84879463176     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.12273     Document Type: Article

References (22)

1. Chen S, Tacy T, Clyman R,. How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude? J Perinatol 2010; 30: 780-5.
2. Hamrick SE, Hansmann G,. Patent ductus arteriosus of the preterm infant. Pediatrics 2010; 125: 1020-30.
3. Sasi A, Deorari A,. Patent ductus arteriosus in preterm infants. Indian Pediatr 2011; 48: 301-8.
4. Van Overmeire B, Van de Broek H, Van Laer P, Weyler J, Vanhaesebrouck P,. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001; 138: 205-11.
5. Yang CZ, Lee J,. Factors affecting successful closure of hemodynamically significant patent ductus arteriosus with indomethacin in extremely low birth weight infants. World J Pediatr 2008; 4: 91-6.
6. Sehgal A, McNamara PJ,. Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus? Eur J Pediatr 2009; 168: 907-14.
7. Suzumura H, Nitta A, Tanaka G, Arisaka O,. Diastolic flow velocity of the left pulmonary artery of patent ductus arteriosus in preterm infants. Pediatr Int 2001; 43: 146-51.
8. Ramos FG, Rosenfeld CR, Roy L, Koch J, Ramaciotti C,. Echocardiographic predictors of symptomatic patent ductus arteriosus in extremely-low-birth-weight preterm neonates. J Perinatol 2010; 30: 535-9.
9. de Lemos JA, McGuire DK, Drazner MH,. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-22.
10. Maher KO, Reed H, Cuadrado A, Simsic J, Mahle WT, Deguzman M, et al. B-type natriuretic peptide in the emergency diagnosis of critical heart disease in children. Pediatrics 2008; 121: e1484-8.
11. Ohashi A, Kaneko K,. Serum brain natriuretic peptide for prediction of successful medical treatment of patent ductus arteriosus in premature infants. J Thorac Cardiovasc Surg 2009; 138: 261-2.
12. da Graca RL, Hassinger DC, Flynn PA, Sison CP, Nesin M, Auld PA,. Longitudinal changes of brain-type natriuretic peptide in preterm neonates. Pediatrics 2006; 117: 2183-9.
13. El-Khuffash A, Molloy EJ,. Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates? Arch Dis Child Fetal Neonatal Ed 2007; 92: F320-4.
14. Hsu JH, Yang SN, Chen HL, Tseng HI, Dai ZK, Wu JR,. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. J Pediatr 2010; 157: 79-84.
15. Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005; 115: e255-61.
16. Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinman CS,. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005; 147: 38-42.
17. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L'Ecuyer T,. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005; 25: 709-13.
18. Czernik C, Lemmer J, Metze B, Koehne PS, Mueller C, Obladen M,. B-type natriuretic peptide to predict ductus intervention in infants <28 weeks. Pediatr Res 2008; 64: 286-90.
19. Attridge JT, Kaufman DA, Lim DS,. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2009; 94: F178-82.
20. Holmström H, Hall C, Thaulow E,. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001; 90: 184-91.
21. Kalra VK, DeBari VA, Zauk A, Kataria P, Myridakis D, Kiblawi F,. Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus. Ann Clin Lab Sci 2011; 41: 131-7.
22. Witthaut R,. Science review: natriuretic peptides in critical illness. Crit Care 2004; 8: 342-9.